Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial-Reference-Cited by-同舟云学术

Pharmacokinetic equivalence of CT‐P39 and reference omalizumab in healthy individuals: A randomised, double‐blind, parallel‐group, Phase 1 trial

Published:2022-11 Issue:11 Volume:12 Page:
ISSN:2045-7022
Container-title:Clinical and Translational Allergy
language:en
Short-container-title:Clinical & Translational All

Author:

Maurer Marcus¹²^ORCID,Saini Sarbjit S.³^ORCID,McLendon Kristi⁴,Wabnitz Paul⁵^ORCID,Kim Sunghyun⁶,Ahn Keumyoung⁶,Kim Suyoung⁶,Lee Sewon⁶,Grattan Clive⁷^ORCID

Affiliation:

1. Institute of Allergology Charité – Universitätsmedizin Berlin Corporate Member of Freie Universität Berlin and Humboldt‐Universität zu Berlin Berlin Germany

2. Allergology and Immunology Fraunhofer Institute for Translational Medicine and Pharmacology (ITMP) Berlin Germany

3. Johns Hopkins University School of Medicine Johns Hopkins University Baltimore Maryland USA

4. Nucleus Network Pty Ltd Herston Queensland Australia

5. cPHARMA Pty Ltd Adelaide South Australia Australia

6. Celltrion, Inc. Incheon Republic of Korea

7. St John's Institute of Dermatology Guy's Hospital London UK

Publisher

Wiley

Subject

Immunology and Allergy,Immunology,Pulmonary and Respiratory Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/clt2.12204

Reference30 articles.

1. Roles of omalizumab in various allergic diseases

2. European Medicines Agency.Xolair. Summary of Product Characteristics.2021. Accessed July 18 2022.https://www.ema.europa.eu/en/documents/product‐information/xolair‐epar‐product‐information_en.pdf

3. US Food and Drug Administration.Xolair. Prescribing Information.2021. Accessed July 18 2022.https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/103976s5239lbl.pdf

4. Global Initiative for Asthma.Global Strategy for Asthma Management and Prevention (2021 Update).2021. Accessed July 18 2022.https://ginasthma.org/wp‐content/uploads/2021/05/GINA‐Main‐Report‐2021‐V2‐WMS.pdf

5. EAACI Biologicals Guidelines—Recommendations for severe asthma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chronic urticaria: unmet needs, emerging drugs, and new perspectives on personalised treatment;The Lancet;2024-07

2. Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessment;Biomedicine & Pharmacotherapy;2023-12

3. Autoreactive IgE: Pathogenic role and therapeutic target in autoimmune diseases;Allergy;2023-08-09